SPARC and pancreatic neoplasm: This has led to studies in various malignancies evaluating the efficacy of nanoparticle albumin-bound (nab)-paclitaxel based upon SPARC expression with correlation in response rates in high SPARC expressers in head and neck cancer patients [14] but inconsistent results in pancreatic cancer patients [5].